Pharmaceutical stocks are in focus as the global drug market is projected to hit $1.21 trillion by 2025, driven by new treatments and increased demand for specialty medicines. AbbVie’s Q3 2025 results exceeded expectations, with revenue of $15.78 billion, up 9.1% from the previous year.

AbbVie announced a 5.5% dividend increase, raising the quarterly cash dividend from $1.64 to $1.73 per share. The stock has climbed 15.18% in the past three months, outperforming the S&P 500. With newer drugs like Skyrizi and Rinvoq performing well, AbbVie’s transition away from Humira has been successful.

AbbVie is a pharmaceutical company that focuses on areas like immunology, neuroscience, oncology, and aesthetics. The stock has gained 22.70% year-to-date and 8.21% over the past 52 weeks. It trades at a forward price-earnings ratio of 21.57x, slightly above the healthcare sector average.

The company has raised its dividend every year for 54 years, with a current dividend yield of 3.22%, well above the sector average of 1.58%. AbbVie is investing in expanding manufacturing capabilities in the U.S. and has raised its 2025 earnings forecast, showing confidence in future growth.

AbbVie’s Q3 earnings showed solid growth, with net revenues reaching $15.776 billion. The company acquired new drugs targeting severe depression and autoimmune diseases, strengthening its position in these markets. AbbVie’s investment in manufacturing expansion reflects a commitment to innovation and growth.

Wall Street analysts have a positive outlook on AbbVie, with price targets indicating potential upside. The company’s performance post-Humira and success with newer drugs like Skyrizi and Rinvoq have garnered praise. With a consensus “Moderate Buy” rating and bullish sentiment, AbbVie’s stock is seen as a promising investment opportunity.

Read more at Yahoo Finance: AbbVie Just Raised Its Dividend by 5.5%. Should You Buy ABBV Stock Here?